Glucose-dependent insulinotropic polypeptide regulates body weight and food intake via GABAergic neurons in mice
Arkadiusz Liskiewicz,Ahmed Khalil,Daniela Liskiewicz,Aaron Novikoff,Gerald Grandl,Gandhari Maity-Kumar,Robert M Gutgesell,Mostafa Bakhti,Aimée Bastidas-Ponce,Oliver Czarnecki,Konstantinos Makris,Heiko Lickert,Annette Feuchtinger,Monica Tost,Callum Coupland,Lisa Ständer,Seun Akindehin,Sneha Prakash,Faiyaz Abrar,Russell L Castelino,Yantao He,Patrick J Knerr,Bin Yang,Wouter F J Hogendorf,Shiqi Zhang,Susanna M Hofmann,Brian Finan,Richard D DiMarchi,Matthias H Tschöp,Jonathan D Douros,Timo D Müller
DOI: https://doi.org/10.1038/s42255-023-00931-7
Abstract:The development of single-molecule co-agonists for the glucagon-like peptide-1 (GLP-1) receptor (GLP-1R) and glucose-dependent insulinotropic polypeptide (GIP) receptor (GIPR) is considered a breakthrough in the treatment of obesity and type 2 diabetes. But although GIPR-GLP-1R co-agonism decreases body weight with superior efficacy relative to GLP-1R agonism alone in preclinical1-3 and clinical studies4,5, the role of GIP in regulating energy metabolism remains enigmatic. Increasing evidence suggests that long-acting GIPR agonists act in the brain to decrease body weight through the inhibition of food intake3,6-8; however, the mechanisms and neuronal populations through which GIP affects metabolism remain to be identified. Here, we report that long-acting GIPR agonists and GIPR-GLP-1R co-agonists decrease body weight and food intake via inhibitory GABAergic neurons. We show that acyl-GIP decreases body weight and food intake in male diet-induced obese wild-type mice, but not in mice with deletion of Gipr in Vgat(also known as Slc32a1)-expressing GABAergic neurons (Vgat-Gipr knockout). Whereas the GIPR-GLP-1R co-agonist MAR709 leads, in male diet-induced obese wild-type mice, to greater weight loss and further inhibition of food intake relative to a pharmacokinetically matched acyl-GLP-1 control, this superiority over GLP-1 vanishes in Vgat-Gipr knockout mice. Our data demonstrate that long-acting GIPR agonists crucially depend on GIPR signaling in inhibitory GABAergic neurons to decrease body weight and food intake.